Skip to main content

Table 3 Cox proportional hazards models of mortality after prison release

From: Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia

 

Model 1

HR (95% CI)

Model 2

HR (95% CI)

Model 3

HR (95% CI)

Methadone

1.33 (0.58–3.05)

1.22 (0.53–2.80)

1.18 (0.49–2.83)

Randomized allocation phase

1.99 (0.82–4.84)

1.84 (0.76–4.46)

1.65 (0.58–4.67)

Methadone*allocation phase

0.69 (0.21–2.23)

0.70 (0.22–2.24)

0.66 (0.19–2.32)

HHRP

1.34 (0.81–2.22)

1.30 (0.78–2.17)

0.99 (0.56–1.76)

Age (years)

  

0.98 (0.93–1.04)

Malay ethnicity

  

0.61 (0.29–1.29)

Married

  

1.97 (0.92–4.21)

Educational attainment

  

1.35 (1.04–1.76)

Employed†

  

0.59 (0.33–1.04)

CD4+ T-cell count‡

 

0.90 (0.82–1.00)

0.84 (0.72–0.97)

HIV symptom index

  

0.97 (0.90–1.05)

History of tuberculosis

  

0.55 (0.24–1.27)

Addiction severity index§

  

0.98 (0.95–1.02)

History of drug injection

  

1.05 (0.38–2.90)

Benzodiazepine use†

  

1.82 (0.81–4.13)

Methamphetamine use†

  

0.83 (0.42–1.62)

Opioid use†

  

2.50 (0.56–11.1)

Alcohol use†

  

2.02 (1.06–3.86)

  1. Randomized allocation phase is an indicator variable for allocation to methadone by randomization versus participant choice. HHRP: Holistic Health and Recovery Program; HR: hazard ratio; CI: confidence interval. †Assessed in the 30 days before incarceration. ‡Represents 100-cell/mm3 change. §Addiction severity index drug composite score